Know Before the Cliff: How AI and Patent Analytics Let You See Generic Competition Coming
Pfizer’s finance team did not need a news alert to know Lipitor was in trouble. By 2010, the company’s own […]
Fix Pharma Forecasts: Common Misinterpretations of the FDA Orange Book That Distort Market Forecasts
Reliable pharmaceutical market forecasting requires moving beyond a simple reading of the FDA Orange Book. Investors and analysts frequently treat
Two Roads to Generic Drug Profits: The US Niche Strategy vs. India’s Mass Market Model
A deep-dive into the economics, IP strategy, and competitive dynamics shaping two divergent paths for branded generic pharmaceutical companies The
Two Roads to Generic Drug Profits: The US Niche Strategy vs. India’s Mass Market Model Read Post »
Stop Patent Hops: Detecting “Evergreening” Patterns Through Sequential FDA Orange Book Listings
The pharmaceutical industry operates on a model where the expiration of a primary patent is no longer the end of
How to stop a 90% revenue crash: Mapping patent thickets to survive the new exclusivity slope
The Cliff Is Real, and the Numbers Are Getting Worse The pharmaceutical revenue cliff is not a metaphor. It is
The Smarter Drug Approval Path Most Companies Still Ignore: A Comparative Analysis of 505(b)(2) and 505(b)(1) Regulatory Pathways
The pharmaceutical industry spent roughly $2.3 billion and 12 years, on average, bringing a single new molecular entity to market
Patent Gaps Pay: The Regional Launch Windows Hidden Inside Abandoned Drug Patents
Every year, pharmaceutical companies abandon thousands of patents. They miss maintenance fee deadlines. They fail to validate patents in markets
Patent Gaps Pay: The Regional Launch Windows Hidden Inside Abandoned Drug Patents Read Post »
De-Risk Your Pipeline: The Definitive Guide to Freedom-to-Operate Analysis in Biopharma
What FTO Actually Means (And What It Doesn’t) The Legal Definition and Its Limits Freedom-to-operate analysis is one of the
De-Risk Your Pipeline: The Definitive Guide to Freedom-to-Operate Analysis in Biopharma Read Post »
How Drug Companies Turn 20-Year Patents Into 40-Year Monopolies
Humira, AbbVie’s blockbuster arthritis drug, generated more than $200 billion in cumulative revenue before biosimilar competitors could reach American patients
How Drug Companies Turn 20-Year Patents Into 40-Year Monopolies Read Post »
